Lung Cancer

To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical. Read More ›

Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial. Read More ›

Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness. Read More ›

The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers. Read More ›

Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors. Read More ›

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›

The open-label, phase 2 VISION study evaluated the efficacy and safety of tepotinib, a highly selective oral MET inhibitor, in patients with advanced NSCLC with MET alterations. Read More ›

Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC. Read More ›

Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation. Read More ›

Page 1 of 8

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: